Paclitaxel-carboplatin and bevacizumab combination with maintenance bevacizumab therapy for metastatic, recurrent, and persistent uterine cervical cancer: An open-label multicenter phase II trial (JGOG1079)-Reference-Cited by-同舟云学术

Paclitaxel-carboplatin and bevacizumab combination with maintenance bevacizumab therapy for metastatic, recurrent, and persistent uterine cervical cancer: An open-label multicenter phase II trial (JGOG1079)

Published:2022-06 Issue:3 Volume:165 Page:413-419
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Tanigawa Terumi,Takeshima Nobuhiro,Ishikawa Hideki,Nishio Shin,Usami Tomoka,Yamawaki Takaharu,Oishi Tetsuro,Ihira Kei,Kato Hisamori,Goto Mayako,Saito Motoaki,Taira Yusuke,Yokoyama Masatoshi,Shoji Tadahiro,Kondo Eiji,Mori Atsushi,Yokoi Takeshi,Iwasa-Inoue Naomi,Hirashima Yasuyuki,Nagasawa Takayuki,Takenaka Motoki,Mikami Mikio,Sugiyama Toru,Enomoto Takayuki

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference24 articles.

1. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study;Monk;J. Clin. Oncol.,2009

2. A randomized, phase III trial of paclitaxel plus carboplatin (TC) versus paclitaxel plus cisplatin (TP) in stage IVb, persistent or recurrent cervical cancer: Japan Clinical Oncology Group study (JCOG0505);Kitagawa;J. Clin. Oncol.,2012

3. A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer;Lorusso;Gynecol. Oncol.,2014

4. Improved survival with bevacizumab in advanced cervical cancer;Tewari;N. Engl. J. Med.,2014

5. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240);Penson;Lancet Oncol.,2015

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New Investigational Drug’s Targeting Various Molecular Pathways for Treatment of Cervical Cancer: Current Status and Future Prospects;Cancer Investigation;2024-07-05

2. Cervical cancer: Novel treatment strategies offer renewed optimism;Pathology - Research and Practice;2024-02

3. Evolving standards and future directions for systemic therapies in cervical cancer;Journal of Gynecologic Oncology;2024

4. Molecular mechanisms augmenting resistance to current therapies in clinics among cervical cancer patients;Medical Oncology;2023-04-15

5. Investigational drugs for recurrent or primary advanced metastatic cervical cancer: what is in the clinical development pipeline?;Expert Opinion on Investigational Drugs;2023-03-04